Interim PET response of Pola-R-CHP predicts outcome in previously untreated CD5-positive diffuse large B-cell lymphoma: a multicenter retrospective study. [PDF]
Sui J +10 more
europepmc +1 more source
Application of a multidimensional and process-oriented evaluation system in PELD bridging therapy for lumbar spinal infections: a self-controlled retrospective study of 27 cases. [PDF]
Wang Y, Yu X, Li J, Yang Y, Chang Z.
europepmc +1 more source
Long-term complete remission following treatment with polatuzumab vedotin, rituximab, and bendamustine in a patient with mantle cell lymphoma relapsing after CAR-T cell therapy: a case report. [PDF]
Sunder-Plassmann V +2 more
europepmc +1 more source
Discursos y manifiestos de Benito Juarez; recopilacion de Angel Pola.
"Reminiscencias ..." [por Felix Romero]: p.
Romero, Felix. +2 more
core
Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial. [PDF]
Matasar M +18 more
europepmc +1 more source
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma. [PDF]
Chavez JC +17 more
europepmc +1 more source
A murine proof-of-concept study of polatuzumab vedotin in combination with venetoclax in experimental therapy of BCL2-positive aggressive lymphomas. [PDF]
Pokorna E +11 more
europepmc +1 more source
Networked Embedded Control Systems: from Modelling to Implementation,
DI BENEDETTO, MARIA DOMENICA +1 more
core +1 more source
Genetic dissection of DNA damage tolerance in Bacillus subtilis: RecA and recombination functions regulate translesion synthesis. [PDF]
Torres R, Alonso JC.
europepmc +1 more source

